| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | SCB |
| Uniprot No | Q96I99 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-432aa |
| 氨基酸序列 | MASPVAAQAGKLLRALALRPRFLAAGSQAVQLTSRRWLNLQEYQSKKLMSDNGVRVQRFFVADTANEALEAAKRLNAKEIVLKAQILAGGRGKGVFNSGLKGGVHLTKDPNVVGQLAKQMIGYNLATKQTPKEGVKVNKVMVAEALDISRETYLAILMDRSCNGPVLVGSPQGGVDIEEVAASNPELIFKEQIDIFEGIKDSQAQRMAENLGFVGPLKSQAADQITKLYNLFLKIDATQVEVNPFGETPEGQVVCFDAKINFDDNAEFRQKDIFAMDDKSENEPIENEAAKYDLKYIGLDGNIACFVNGAGLAMATCDIIFLNGGKPANFLDLGGGVKEAQVYQAFKLLTADPKVEAILVNIFGGIVNCAIIANGITKACRELELKVPLVVRLEGTNVQEAQKILNNSGLPITSAIDLEDAAKKAVASVAKK |
| 预测分子量 | 46,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SCB重组蛋白的3篇虚构参考文献示例，供格式参考：
---
1. **文献名称**: *"High-yield expression and purification of SCB recombinant protein in E. coli for antigenic studies"*
**作者**: Zhang L, et al.
**摘要**: 研究通过优化大肠杆菌表达系统，实现SCB重组蛋白的高效可溶性表达，利用亲和层析和尺寸排阻色谱纯化，证实其与特定抗体的结合活性，为疫苗开发提供基础。
2. **文献名称**: *"Structural characterization of SCB recombinant protein using cryo-EM and its role in cellular adhesion"*
**作者**: Gupta R, et al.
**摘要**: 通过冷冻电镜解析SCB重组蛋白的3D结构，揭示其与宿主细胞表面受体的结合机制，功能实验验证其在病原体入侵中的关键作用，为靶向药物设计提供依据。
3. **文献名称**: *"Functional analysis of SCB recombinant protein in a murine model of autoimmune disease"*
**作者**: Tanaka K, et al.
**摘要**: 在哺乳动物细胞中表达SCB重组蛋白，并证明其通过调节免疫细胞活性缓解小鼠自身免疫疾病症状，提出其作为潜在治疗分子的应用前景。
---
**注**：以上文献为示例性内容，实际引用时需检索真实数据库(如PubMed、Web of Science)并核实信息。如需进一步协助，请提供更具体的研究背景或关键词。
SCB recombinant proteins are engineered using advanced genetic technologies to produce highly purified, functional proteins for diverse biomedical applications. Derived from recombinant DNA technology, these proteins are synthesized by inserting target genes into host systems (e.g., bacterial, mammalian, or insect cells), enabling precise control over protein expression and post-translational modifications. This method overcomes limitations of traditional protein extraction, such as low yield, batch variability, and contamination risks.
The development of SCB recombinant proteins aligns with growing demands in drug discovery, therapeutics, and diagnostic research. For instance, they serve as critical tools in studying protein-protein interactions, antibody production, and cell signaling pathways. Their applications extend to therapeutic areas like oncology, immunology, and infectious diseases, where recombinant cytokines, enzymes, or antibodies are used to modulate biological processes or as drug candidates.
SCB’s platform emphasizes scalability and customization, offering proteins with high batch-to-batch consistency and species-specific isoforms. Quality assurance includes rigorous testing for endotoxin levels, bioactivity, and purity via SDS-PAGE or mass spectrometry. With the global recombinant protein market expanding rapidly (projected to exceed $1.2 billion by 2028), SCB’s innovations address the need for reliable, cost-effective reagents, accelerating both basic research and clinical development. Their products are particularly valuable in vaccine development and biopharmaceutical manufacturing, where precise protein characterization is paramount. By integrating cutting-edge expression systems and purification techniques, SCB contributes to advancing personalized medicine and targeted therapies.
×
